[1]吕玉潸.艾普拉唑序贯疗法与标准四联疗法对慢性萎缩性胃炎患者症状及胃黏膜病理积分的影响[J].医学信息,2026,39(01):95-99.[doi:10.3969/j.issn.1006-1959.2026.01.016]
　LYU Yushan.Effect of Ilaprazole Sequential Therapy and Standard Quadruple Therapy on Symptomsand Pathological Scores of Gastric Mucosa in Patients with Chronic Atrophic Gastritis[J].Journal of Medical Information,2026,39(01):95-99.[doi:10.3969/j.issn.1006-1959.2026.01.016]
点击复制

艾普拉唑序贯疗法与标准四联疗法对慢性萎缩性胃炎患者症状及胃黏膜病理积分的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
39卷
期数:
2026年01期
页码:
95-99
栏目:
临床证据信息
出版日期:
2026-01-01

文章信息/Info

Title:
Effect of Ilaprazole Sequential Therapy and Standard Quadruple Therapy on Symptomsand Pathological Scores of Gastric Mucosa in Patients with Chronic Atrophic Gastritis
文章编号:
1006-1959（2026）01-0095-05
作者:
吕玉潸
武宁县人民医院急诊科，江西 武宁 332300
Author(s):
LYU Yushan
Emergency Department of Wuning County People′s Hospital, Wuning 332300, Jiangxi, China
关键词:
艾普拉唑序贯疗法; 标准四联疗法; 慢性萎缩性胃炎; 胃黏膜病理积分
Keywords:
Ilaprazole sequential therapy;  Standard quadruple therapy;  Chronic atrophic gastritis;  Gastric mucosal pathological scores
分类号:
R573.3
DOI:
10.3969/j.issn.1006-1959.2026.01.016
文献标志码:
A
摘要:
目的 探讨艾普拉唑序贯疗法与标准四联疗法对慢性萎缩性胃炎（CAG）患者症状及胃黏膜病理积分的影响。方法 选取2022年1月-2024年12月在武宁县人民医院治疗的52例CAG患者，按随机数字表法分为对照组和观察组，每组26例。对照组采用标准四联疗法，观察组采用艾普拉唑序贯疗法。比较两组临床疗效、炎性因子[肿瘤坏死因子-α（TNF-α）、C反应蛋白（CRP）、白细胞介素-6（IL-6）]水平、症状评分（上腹痛、上腹胀满、早饱、嗳气、恶心、全身症状、精神症状）、胃黏膜病理积分（黏膜表面状态、黏膜色泽、黏膜分泌物、黏膜组织学、黏膜血运）。结果 观察组总有效率（96.15%）高于对照组（73.08%）（P＜0.05）。两组炎性因子水平治疗后均降低，且观察组低于对照组（P＜0.05）；两组症状评分均下降，且观察组低于对照组（P＜0.05）；两组胃黏膜病理积分均下降，且观察组低于对照组（P＜0.05）。结论 艾普拉唑序贯疗法能改善CAG患者症状，降低胃黏膜病理积分和炎性因子水平，疗效优于标准四联疗法，值得应用。
Abstract:
Objective To investigate the effects of ilaprazole sequential therapy and standard quadruple therapy on symptoms and gastric mucosal pathological scores in patients with chronic atrophic gastritis (CAG). Methods A total of 52 CAG patients treated in Wuning County People′s Hospital from January 2022 to December 2024 were selected and divided into control group and observation group according to random number table method, with 26 patients in each group. The control group was treated with standard quadruple therapy, and the observation group was treated with ilaprazole sequential therapy. The clinical efficacy, levels of inflammatory factors [tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), interleukin-6 (IL-6)], symptom scores (upper abdominal pain, upper abdominal distension, early satiety, belching, nausea, systemic symptoms, mental symptoms), gastric mucosal pathological scores (mucosal surface state, mucosal color, mucosal secretion, mucosal histology, mucosal blood supply) were compared between the two groups. Results The total effective rate of the observation group (96.15%) was higher than that of the control group (73.08%) (P<0.05). The levels of inflammatory factors in the two groups decreased after treatment, and those in the observation group were lower than those in the control group (P<0.05). The symptom scores of the two groups were decreased, and those of the observation group were lower than those of the control group (P<0.05). The pathological scores of gastric mucosa in both groups decreased, and those in the observation group were lower than those in the control group (P<0.05). Conclusion Ilaprazole sequential therapy can improve the symptoms of CAG patients, reduce the pathological score of gastric mucosa and the level of inflammatory factors. The curative effect is better than that of standard quadruple therapy, which is worthy of application.

参考文献/References:

[1]李艳,赵婷.标准四联联合荆花胃康胶丸对Hp阳性慢性萎缩性胃炎病人血清胃泌素17、PG及免疫功能的影响[J].蚌埠医学院学报,2023,48(2):222-225.[2]马耿,张丽贤.标准四联疗法对幽门螺杆菌阳性慢性萎缩性胃炎患者血清GH、PGⅠ、PGⅡ、IL、TGF-β1水平及预后的影响分析[J].中国医学前沿杂志(电子版),2019,11(1):79-82.[3]孙洁纯,黄胜林,刘婷婷,等.乌梅丸联合抗Hp四联根除疗法治疗Hp感染寒热错杂型慢性萎缩性胃炎的疗效及对Hp根除率和IL-1β、IL-6的影响[J].广州中医药大学学报,2023,40(8):1916-1922.[4]倪航,关晓辉.荆花胃康联合四联疗法对Hp阳性慢性萎缩性胃炎患者的临床疗效[J].北华大学学报(自然科学版),2023,24(5):626-629.[5]李多,王锐,于永强,等.雷贝拉唑、阿莫西林、克拉霉素联合枳术宽中胶囊治疗老年幽门螺杆菌阳性慢性萎缩性胃炎[J].山东医药,2018,58(3):78-80.[6]王瑞昕,张声生,周强.荆花胃康胶丸联合标准四联疗法对Hp相关性慢性胃炎患者的疗效研究[J].中国中西医结合消化杂志,2021,29(9):610-614.[7]李霞.布拉酵母菌散荆花胃康胶丸联合标准四联疗法治疗幽门螺杆菌相关性胃炎及十二指肠溃疡疗效观察[J].中国药物与临床,2018,18(4):600-601.[8]翟琦,陈英杰,宣佶,等.双歧杆菌三联活菌胶囊联合四联疗法对Hp阳性慢性浅表性胃炎炎症-氧化应激水平的影响[J].贵州医科大学学报,2020,45(2):209-213,218.[9]郑长清,张喆.东方胃药联合标准三联疗法与含铋剂四联疗法治疗Hp相关性胃炎及消化性溃疡患者临床疗效对比分析[J].实用药物与临床,2022,25(1):46-50. [10]康影,刘昊,董笑一,等.茵连和胃颗粒联合四联疗法治疗Hp相关性胃炎的疗效分析[J].中国中西医结合消化杂志,2022,30(11):765-768.[11]黎洪,李晓云.艾普拉唑联合瑞巴派特治疗阿司匹林相关性胃炎的临床疗效[J].广西医学,2018,40(21):2613-2614.[12]吴大威,杨玉双,崔青志,等.艾普拉唑序贯治疗消化性溃疡的临床研究及对血清胃泌素与胃泌素基因表达的影响[J].河北医学,2018,24(5):791-794.[13]黄天红,刘玉峰,徐伟松.艾普拉唑治疗消化性溃疡出血患者的临床研究[J].中国临床药理学杂志,2023,39(19):2748-2751.[14]苏国安.艾普拉唑联合铋剂标准四联对幽门螺杆菌相关性慢性胃炎治疗效果分析[J].中国药物与临床,2021,21(3):408-409.[15]苏颜平,赵瑞.艾普拉唑联合康复新液治疗胃溃疡临床疗效观察[J].山西医药杂志,2020,49(18):2498-2500.[16]崔海沫,姜葵,王磊,等.艾普拉唑与雷贝拉唑治疗内镜黏膜下剥离术后人工溃疡愈合的效果对比[J].广东医学,2021,42(1):71-75.[17]柯楠,何建芳,秦宝山.艾普拉唑序贯疗法对消化性溃疡治疗效果及血清学指标的影响[J].药物评价研究,2020,43(7):1339-1342.[18]施新华,施弼华,崔志俊.艾普拉唑联合阿莫西林治疗消化性溃疡的疗效观察[J].药物评价研究,2019,42(11):2186-2189.[19]宋金铭,赵保团,张乃卫,等.瑞巴特联合呋喃唑酮治疗幽门螺杆菌阳性消化性溃疡的疗效分析[J].现代消化及介入诊疗,2021,26(10):1290-1293.[20]谭惠璇.艾普拉唑结合瑞巴派特对消化性溃疡患者愈合情况影响[J].山西医药杂志,2020,49(17):2340-2342.

更新日期/Last Update: 1900-01-01